ClinicalTrials.Veeva
Menu

Find clinical trials for Asthma in Milano, Lombardia

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pulmonary Eosinophilia
Nasal Polyps
Rhinosinusitis
Allergic Rhinitis
Rhinitis
Sinusitis
Respiration Disorders

Asthma trials near Milano, Lombardia, ITA:

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)

in patients ≥ 6 to \< 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations ...

Enrolling
Asthma
Drug: Placebo
Drug: Benralizumab

Phase 3

AstraZeneca
AstraZeneca

Milano, Italy and 83 other locations

Self-management strategies for asthma, including patients engagement and adherence to personalised action plans with advice on recognizing a...

Enrolling
Asthma
Other: Optimized self-management of asthma
Other: Conventional self-management of asthma
RESTECH

Pavia, Italy and 8 other locations

to budesonide in children from 6 to less than 12 years of age with asthma.* The study duration will be up to 37 weeks including an investiga...

Enrolling
Asthma
Drug: QMF149
Drug: Budesonide

Phase 3

Novartis
Novartis

Pavia, PV, Italy and 51 other locations

treatment in children 2 to \<6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze. The study will be conducted i...

Enrolling
Asthma
Wheezing
Drug: Placebo
Drug: Dupilumab

Phase 3

Sanofi
Sanofi

Milan, Lombardia, Italy and 57 other locations

and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma...

Enrolling
Asthma
Drug: Atuliflapon
Drug: Placebo

Phase 2

AstraZeneca
AstraZeneca

Milano, Italy and 381 other locations

of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all partici...

Active, not recruiting
Asthma
Biological: GSK3511294 (Depemokimab)
Biological: Mepolizumab

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Milano, Italy and 419 other locations

Locations recently updated

variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma...

Active, not recruiting
Asthma
Drug: BFF pMDI 320/9 μg
Drug: BFF MDI 320/9.6 μg

Phase 3

AstraZeneca
AstraZeneca

Casatenovo, Italy and 360 other locations

the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler in adults and adolescents with inadequately controlled asthma...

Active, not recruiting
Asthma
Drug: BD MDI 320 μg
Drug: Open-label Symbicort TBH 320/9 μg

Phase 3

AstraZeneca
AstraZeneca

Tradate, Italy and 142 other locations

administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled c...

Enrolling
Asthma
Device: Inhaler
Drug: AZD8630

Phase 2

AstraZeneca
AstraZeneca

Milano, Italy and 218 other locations

profile of GSK3511294 (Depemokimab) in participants with severe asthma with an eosinophilic phenotype following completion of clinical studi...

Active, not recruiting
Asthma
Biological: GSK3511294 (Depemokimab)

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Milano, Italy and 156 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems